
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp reported third quarter 2025 revenue of $21.5 million, marking a 5% year-over-year growth driven by the increasing adoption of its Zephyr Endobronchial Valve. The company maintained a solid 75% gross margin, with gross profit improving to $16.1 million, while slightly narrowing its net loss to $14 million, suggesting effective cost management and a commitment to operational efficiency. With ongoing international expansion and disciplined investment in revenue-generating initiatives, alongside advancements in their pipeline and leadership, Pulmonx is well-positioned for sustained growth in the evolving medical technology sector.
Bears say
Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, marking a decline from Q2's $23.9 million and indicating a slower revenue growth trajectory, which contributed to management's guidance cut for the year to $90 million–$92 million. The company is experiencing execution risks in product models alongside challenges related to product mix and conversion timing, leading to pressures on both top-line growth and gross margins, which fell from 72% in Q2. A management transition with the return of Glen French as CEO and the appointment of Derrick Sung as COO/CFO further complicates the company's operational stability, impacting investor confidence.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares